PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI)
News | SNMMI
Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease

June 28, 2023 — A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese ...

Time June 28, 2023
arrow
Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.
News | SNMMI
Nizar A. Mullani Receives SNMMI 2023 Georg Charles de Hevesy Nuclear Pioneer Award

June 26, 2023 — Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has ...

Time June 26, 2023
arrow
News | SNMMI
Study on Value of 68Ga-FAPI PET/CT Imaging for Evaluation of Disease Activity in Rheumatoid Arthritis presented during SNMMI 2023

June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease ...

Time June 26, 2023
arrow
During its 2023 Annual Meeting, the Image of the Year was selected by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and represents research presented which reports on the ability of a novel theranostic pair to successfully detect metastatic pancreatic cancer and provide a means of selecting appropriate treatments.
News | SNMMI
Image of the Year and Research Announced at SNMMI 2023 on Theranostic Pair for Early Detection and Effective Treatment of Pancreatic Cancer

June 26, 2023 — A first-in-human evaluation of the novel theranostic pair 68Ga-DOTA-5G / 177Lu-DOTA-ABM-5G has confirmed ...

Time June 26, 2023
arrow
A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated
News | SNMMI
Translational PET Tracer Visualizes Brain Cholesterol Metabolism

June 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol ...

Time June 25, 2023
arrow
News | SNMMI
Ultra-High Resolution Brain PET Scanner Visualizes and Quantifies Brainstem Nuclei for the First Time

June 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously ...

Time June 24, 2023
arrow
 A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging.
News | SNMMI
New Whole-Body PET Technology Offers Cost-Effective Solution to Improve Image Resolution and Sensitivity

June 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has ...

Time June 24, 2023
arrow
POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023
News | Prostate Cancer
Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

June 21, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 21, 2023
arrow
The first patient has been scanned in a Phase I clinical trial for an investigational fluorine-18 (18F) CD8-targeted imaging radiopharmaceutical
News | Radiopharmaceuticals and Tracers
First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

June 15, 2023 — With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare ...

Time June 15, 2023
arrow
A type of artificial intelligence (AI), Deep Learning (DL) technology can advance medical imaging capabilities by providing more robust, accurate, and data-driven information as well as support more efficient workflows and exams
News | Artificial Intelligence
GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

May 31, 2023 — GE HealthCare announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning ...

Time May 31, 2023
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
arrow
In March 2023, Appropriate Use Criteria (AUC) for ER-targeted PET imaging was also published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
News | Breast Imaging
GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

May 25, 2023 — GE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN ...

Time May 25, 2023
arrow
UCLA investigators present the latest cancer research at the American Society of Clinical Oncology annual meeting June 2 to June 6 in Chicago
News | Radiation Oncology
Targeted Therapy for Early Breast Cancer, Progress Treating Recurrent Glioma, PSMA PET Scan Advances Research Presented

May 22, 2023 — Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest ...

Time May 22, 2023
arrow
Parametric maps of amyloid deposition in healthy control participants (A and B) and blast-exposed military instructors (C and D) at baseline (A and C) and follow-up (B and D). The blue-to-red scale indicates the frequency of statistically abnormal amyloid uptake in a particular brain voxel. Whereas no abnormal amyloid uptake was identified at baseline or follow-up in healthy control participants (A, B), amyloid deposition occurred most frequently in blast-exposed participants in the superior parietal lobule
News | PET Imaging
Recurrent Brain Trauma May Increase Alzheimer’s Risk

May 22, 2023 — New research finds that the brains of otherwise healthy military personnel who are exposed to explosions ...

Time May 22, 2023
arrow
Does a new or increasing contrast enhancement on T1 MRI represent a consequence of treatment or progressive/recurrent tumor? This common clinical dilemma can be resolved by amino acid PET with good diagnostic accuracy.
News | PET Imaging
Amino Acid PET Successfully Differentiates Recurrent Brain Metastases, Reducing Invasive Procedures and Overtreatment

May 12, 2023 — A newly published meta-analysis indicates that amino acid PET can accurately differentiate recurrent or ...

Time May 12, 2023
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer
News | Prostate Cancer
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
Using a harmless glucose solution, the procedure generates reliable results
News | Magnetic Resonance Imaging (MRI)
Pioneering MRI Imaging Method Captures Brain Glucose Metabolism Without the Need for Administration of Radioactive Substances

May 2, 2023 — Metabolic disorders are involved in many common health conditions such as Alzheimer's, depression ...

Time May 02, 2023
arrow
GE HealthCare will deliver the Cyclotrons to ALISA’s laboratory facility in Midrand, South Africa early next year, giving patients in Africa access to medical advancements
News | PET Imaging
GE HealthCare and Axim Life Isotopes South Africa (ALISA) Collaborate to Expand Access to Molecular Imaging in South Africa and Drive Precision Care

April 28, 2023 — GE HealthCare to deliver two Cyclotrons next year, expanding South Africa’s capacity to produce ...

Time April 28, 2023
arrow
New radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) provides powerhouse combination of capabilities and expertise to advance patient care
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

April 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 03, 2023
arrow
newly published literature review sheds light on how nuclear medicine brain imaging can help evaluate the biological changes that cause chemotherapy-related cognitive impairment (CRCI), commonly known as chemo-brain
News | Molecular Imaging
Molecular Imaging Offers Insight Into Chemo-brain

March 29, 2023 — A newly published literature review sheds light on how nuclear medicine brain imaging can help evaluate ...

Time March 29, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now